Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody

Affiliations

¹ Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
² Department of Hematology, Tel-Aviv Sourasky (Ichilov) Medical Center, Tel Aviv University, Tel Aviv, Israel.
³ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
⁴ Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.
⁵ Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
⁶ Department of Malignant Haematology, The Alfred Hospital, Melbourne, VIC, Australia.
⁷ NCT/UCC Early Clinical Trial Unit, Universitätsklinikum Carl Gustav Carus an der Technische Universität, Dresden, Germany.
⁸ Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
⁹ Winship Cancer Institute, Emory University, Atlanta, GA, USA.
¹⁰ Department of Hematology, Niguarda Hospital, Niguarda, Milan, Italy.
¹¹ Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain.
¹² Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
¹³ Novartis Institutes for BioMedical Research, Basel, Switzerland.
¹⁴ Novartis Institutes for BioMedical Research, Cambridge, MA, USA. serena.de_vita@novartis.com.
¹⁵ Novartis Institutes for BioMedical Research, Cambridge, MA, USA. haihui.lu@novartis.com.

^# Contributed equally.

Published Erratum

Marc S Raab et al. Leukemia. 2025 Jun.

. 2025 Jun;39(6):1545.

doi: 10.1038/s41375-025-02516-7.

¹ Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
² Department of Hematology, Tel-Aviv Sourasky (Ichilov) Medical Center, Tel Aviv University, Tel Aviv, Israel.
³ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
⁴ Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.
⁵ Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
⁶ Department of Malignant Haematology, The Alfred Hospital, Melbourne, VIC, Australia.
⁷ NCT/UCC Early Clinical Trial Unit, Universitätsklinikum Carl Gustav Carus an der Technische Universität, Dresden, Germany.
⁸ Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
⁹ Winship Cancer Institute, Emory University, Atlanta, GA, USA.
¹⁰ Department of Hematology, Niguarda Hospital, Niguarda, Milan, Italy.
¹¹ Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain.
¹² Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
¹³ Novartis Institutes for BioMedical Research, Basel, Switzerland.
¹⁴ Novartis Institutes for BioMedical Research, Cambridge, MA, USA. serena.de_vita@novartis.com.
¹⁵ Novartis Institutes for BioMedical Research, Cambridge, MA, USA. haihui.lu@novartis.com.

^# Contributed equally.

No abstract available

Erratum for

Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody.
Raab MS, Cohen YC, Schjesvold F, Aardalen K, Oka A, Spencer A, Wermke M, Souza AD, Kaufman JL, Cafro AM, Ocio EM, Doki N, Henson K, Trabucco G, Carrion A, Bender FC, Juif PE, Fessehatsion A, Fan L, Stonehouse JP, Blankenship JW, Granda B, De Vita S, Lu H. Raab MS, et al. Leukemia. 2023 Jun;37(6):1349-1360. doi: 10.1038/s41375-023-01883-3. Epub 2023 Apr 6. Leukemia. 2023. PMID: 37024520